ClinicaliQ Trial Snapshot
- A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy — Recruiting • Phase II • NCT06537999.
- Phase 2 trial testing Claseprubart safety and effectiveness in adults with multifocal motor neuropathy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of Claseprubart (DNTH103) in participants with multifocal motor neuropathy (MMN). Conditions: Multifocal Motor Neuropathy Interventions: Claseprubart, Placebo Lead Sponsor: Dianthus Therapeutics Planned Enrollment: 36 participants